Clinical-demographic markers for improving diabetes mellitus diagnosis in people with tuberculosis in Tanzania

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Clinical-demographic markers for improving diabetes mellitus diagnosis in people with tuberculosis in Tanzania. / Byashalira, Kenneth Cleophace; Chamba, Nyasatu Godfrey; Alkabab, Yosra; Mbelele, Peter Masunga; Ntinginya, Nyanda Elias; Ramaiya, Kaushik Laxmidas; Alimohamed, Mohamed Zahir; Heysell, Scott Kirkland; Mmbaga, Blandina Theophil; Bygbjerg, Ib Christian; Christensen, Dirk Lund; Mpagama, Stellah George; Lillebaek, Troels; ADEPT Consortium.

I: BMC Infectious Diseases, Bind 22, Nr. 1, 260, 2022.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Byashalira, KC, Chamba, NG, Alkabab, Y, Mbelele, PM, Ntinginya, NE, Ramaiya, KL, Alimohamed, MZ, Heysell, SK, Mmbaga, BT, Bygbjerg, IC, Christensen, DL, Mpagama, SG, Lillebaek, T & ADEPT Consortium 2022, 'Clinical-demographic markers for improving diabetes mellitus diagnosis in people with tuberculosis in Tanzania', BMC Infectious Diseases, bind 22, nr. 1, 260. https://doi.org/10.1186/s12879-022-07249-x

APA

Byashalira, K. C., Chamba, N. G., Alkabab, Y., Mbelele, P. M., Ntinginya, N. E., Ramaiya, K. L., Alimohamed, M. Z., Heysell, S. K., Mmbaga, B. T., Bygbjerg, I. C., Christensen, D. L., Mpagama, S. G., Lillebaek, T., & ADEPT Consortium (2022). Clinical-demographic markers for improving diabetes mellitus diagnosis in people with tuberculosis in Tanzania. BMC Infectious Diseases, 22(1), [260]. https://doi.org/10.1186/s12879-022-07249-x

Vancouver

Byashalira KC, Chamba NG, Alkabab Y, Mbelele PM, Ntinginya NE, Ramaiya KL o.a. Clinical-demographic markers for improving diabetes mellitus diagnosis in people with tuberculosis in Tanzania. BMC Infectious Diseases. 2022;22(1). 260. https://doi.org/10.1186/s12879-022-07249-x

Author

Byashalira, Kenneth Cleophace ; Chamba, Nyasatu Godfrey ; Alkabab, Yosra ; Mbelele, Peter Masunga ; Ntinginya, Nyanda Elias ; Ramaiya, Kaushik Laxmidas ; Alimohamed, Mohamed Zahir ; Heysell, Scott Kirkland ; Mmbaga, Blandina Theophil ; Bygbjerg, Ib Christian ; Christensen, Dirk Lund ; Mpagama, Stellah George ; Lillebaek, Troels ; ADEPT Consortium. / Clinical-demographic markers for improving diabetes mellitus diagnosis in people with tuberculosis in Tanzania. I: BMC Infectious Diseases. 2022 ; Bind 22, Nr. 1.

Bibtex

@article{4e2889f2bef8435f9763bc90b7a98e16,
title = "Clinical-demographic markers for improving diabetes mellitus diagnosis in people with tuberculosis in Tanzania",
abstract = "BACKGROUND: Tuberculosis (TB) control is threatened by an increasing prevalence of diabetes mellitus (DM), particularly in endemic countries. Screening for DM is not routinely implemented in Tanzania; therefore, we aimed to screen for DM at TB diagnosis using clinical-demographic markers.METHODS: Our cross-sectional study recruited TB patients who received anti-TB treatment between October 2019 and September 2020 at health care facilities in three regions from Tanzania. Patients were screened for DM using DM symptoms (polydipsia, polyphagia and polyuria) and random blood glucose (RBG) testing. Patients with a history of DM and those with no history of DM but an RBG ≥ 7.8 mmol/L had point-of-care glycated haemoglobin (HbA1c) testing, and were considered to have DM if HbA1c was ≥ 48 mmol/mol.RESULTS: Of 1344 TB patients, the mean age was 41.0 (± 17.0) years, and 64.7% were male. A total of 1011 (75.2%) had pulmonary TB, and 133 (10.4%) had at least one DM symptom. Overall, the prevalence of DM was 7.8%, of which 36 (2.8%) TB patients with no history of DM were newly diagnosed with DM by RBG testing. TB/DM patients were older than those with only TB (50.0 ± 14.0 years vs 40.0 ± 17.0 years, p < 0.001). Patients with RBG ≥ 7.8 mmol/L were more likely to have pulmonary TB (p = 0.003), age ≥ 35 years (p = 0.018), and have at least one DM symptom (p < 0.001). There was a substantial agreement (Kappa = 0.74) between the on-site glucometer and point-of-care HbA1c tests in detecting DM range of hyperglycemia.CONCLUSION: The implementation of clinical-demographic markers and blood glucose screening identified the overall prevalence of DM and those at risk of DM in TB patients. Clinical-demographic markers are independent predictors for DM range hyperglycemia and highlight the importance of further diagnostic testing and early co-management of TB and DM.",
keywords = "Adult, Cross-Sectional Studies, Diabetes Mellitus/diagnosis, Humans, Male, Prevalence, Tanzania/epidemiology, Tuberculosis/complications, Tuberculosis, Diabetes Mellitus, Type 2, Diagnostic, Tanzania, Faculty of Health and Medical Sciences",
author = "Byashalira, {Kenneth Cleophace} and Chamba, {Nyasatu Godfrey} and Yosra Alkabab and Mbelele, {Peter Masunga} and Ntinginya, {Nyanda Elias} and Ramaiya, {Kaushik Laxmidas} and Alimohamed, {Mohamed Zahir} and Heysell, {Scott Kirkland} and Mmbaga, {Blandina Theophil} and Bygbjerg, {Ib Christian} and Christensen, {Dirk Lund} and Mpagama, {Stellah George} and Troels Lillebaek and {ADEPT Consortium}",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
doi = "10.1186/s12879-022-07249-x",
language = "English",
volume = "22",
journal = "B M C Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Clinical-demographic markers for improving diabetes mellitus diagnosis in people with tuberculosis in Tanzania

AU - Byashalira, Kenneth Cleophace

AU - Chamba, Nyasatu Godfrey

AU - Alkabab, Yosra

AU - Mbelele, Peter Masunga

AU - Ntinginya, Nyanda Elias

AU - Ramaiya, Kaushik Laxmidas

AU - Alimohamed, Mohamed Zahir

AU - Heysell, Scott Kirkland

AU - Mmbaga, Blandina Theophil

AU - Bygbjerg, Ib Christian

AU - Christensen, Dirk Lund

AU - Mpagama, Stellah George

AU - Lillebaek, Troels

AU - ADEPT Consortium

N1 - © 2022. The Author(s).

PY - 2022

Y1 - 2022

N2 - BACKGROUND: Tuberculosis (TB) control is threatened by an increasing prevalence of diabetes mellitus (DM), particularly in endemic countries. Screening for DM is not routinely implemented in Tanzania; therefore, we aimed to screen for DM at TB diagnosis using clinical-demographic markers.METHODS: Our cross-sectional study recruited TB patients who received anti-TB treatment between October 2019 and September 2020 at health care facilities in three regions from Tanzania. Patients were screened for DM using DM symptoms (polydipsia, polyphagia and polyuria) and random blood glucose (RBG) testing. Patients with a history of DM and those with no history of DM but an RBG ≥ 7.8 mmol/L had point-of-care glycated haemoglobin (HbA1c) testing, and were considered to have DM if HbA1c was ≥ 48 mmol/mol.RESULTS: Of 1344 TB patients, the mean age was 41.0 (± 17.0) years, and 64.7% were male. A total of 1011 (75.2%) had pulmonary TB, and 133 (10.4%) had at least one DM symptom. Overall, the prevalence of DM was 7.8%, of which 36 (2.8%) TB patients with no history of DM were newly diagnosed with DM by RBG testing. TB/DM patients were older than those with only TB (50.0 ± 14.0 years vs 40.0 ± 17.0 years, p < 0.001). Patients with RBG ≥ 7.8 mmol/L were more likely to have pulmonary TB (p = 0.003), age ≥ 35 years (p = 0.018), and have at least one DM symptom (p < 0.001). There was a substantial agreement (Kappa = 0.74) between the on-site glucometer and point-of-care HbA1c tests in detecting DM range of hyperglycemia.CONCLUSION: The implementation of clinical-demographic markers and blood glucose screening identified the overall prevalence of DM and those at risk of DM in TB patients. Clinical-demographic markers are independent predictors for DM range hyperglycemia and highlight the importance of further diagnostic testing and early co-management of TB and DM.

AB - BACKGROUND: Tuberculosis (TB) control is threatened by an increasing prevalence of diabetes mellitus (DM), particularly in endemic countries. Screening for DM is not routinely implemented in Tanzania; therefore, we aimed to screen for DM at TB diagnosis using clinical-demographic markers.METHODS: Our cross-sectional study recruited TB patients who received anti-TB treatment between October 2019 and September 2020 at health care facilities in three regions from Tanzania. Patients were screened for DM using DM symptoms (polydipsia, polyphagia and polyuria) and random blood glucose (RBG) testing. Patients with a history of DM and those with no history of DM but an RBG ≥ 7.8 mmol/L had point-of-care glycated haemoglobin (HbA1c) testing, and were considered to have DM if HbA1c was ≥ 48 mmol/mol.RESULTS: Of 1344 TB patients, the mean age was 41.0 (± 17.0) years, and 64.7% were male. A total of 1011 (75.2%) had pulmonary TB, and 133 (10.4%) had at least one DM symptom. Overall, the prevalence of DM was 7.8%, of which 36 (2.8%) TB patients with no history of DM were newly diagnosed with DM by RBG testing. TB/DM patients were older than those with only TB (50.0 ± 14.0 years vs 40.0 ± 17.0 years, p < 0.001). Patients with RBG ≥ 7.8 mmol/L were more likely to have pulmonary TB (p = 0.003), age ≥ 35 years (p = 0.018), and have at least one DM symptom (p < 0.001). There was a substantial agreement (Kappa = 0.74) between the on-site glucometer and point-of-care HbA1c tests in detecting DM range of hyperglycemia.CONCLUSION: The implementation of clinical-demographic markers and blood glucose screening identified the overall prevalence of DM and those at risk of DM in TB patients. Clinical-demographic markers are independent predictors for DM range hyperglycemia and highlight the importance of further diagnostic testing and early co-management of TB and DM.

KW - Adult

KW - Cross-Sectional Studies

KW - Diabetes Mellitus/diagnosis

KW - Humans

KW - Male

KW - Prevalence

KW - Tanzania/epidemiology

KW - Tuberculosis/complications

KW - Tuberculosis

KW - Diabetes Mellitus, Type 2

KW - Diagnostic

KW - Tanzania

KW - Faculty of Health and Medical Sciences

U2 - 10.1186/s12879-022-07249-x

DO - 10.1186/s12879-022-07249-x

M3 - Journal article

C2 - 35296241

VL - 22

JO - B M C Infectious Diseases

JF - B M C Infectious Diseases

SN - 1471-2334

IS - 1

M1 - 260

ER -

ID: 300669873